FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967579846> ?p ?o ?g. }

• W1967579846 endingPage "4845" @default.
• W1967579846 startingPage "4836" @default.
• W1967579846 abstract "Article3 September 2001free access Separate SCFCDC4 recognition elements target Cdc6 for proteolysis in S phase and mitosis Gordon Perkins Gordon Perkins Present address: Department of Immunology, UCL Medical School, Windeyer Building, 46 Cleveland Street, London, W1P 6DB UK Search for more papers by this author Lucy S. Drury Lucy S. Drury ICRF Clare Hall Laboratories, South Mimms, EN6 3LD UK Search for more papers by this author John F.X. Diffley Corresponding Author John F.X. Diffley ICRF Clare Hall Laboratories, South Mimms, EN6 3LD UK Search for more papers by this author Gordon Perkins Gordon Perkins Present address: Department of Immunology, UCL Medical School, Windeyer Building, 46 Cleveland Street, London, W1P 6DB UK Search for more papers by this author Lucy S. Drury Lucy S. Drury ICRF Clare Hall Laboratories, South Mimms, EN6 3LD UK Search for more papers by this author John F.X. Diffley Corresponding Author John F.X. Diffley ICRF Clare Hall Laboratories, South Mimms, EN6 3LD UK Search for more papers by this author Author Information Gordon Perkins2, Lucy S. Drury1 and John F.X. Diffley 1 1ICRF Clare Hall Laboratories, South Mimms, EN6 3LD UK 2Present address: Department of Immunology, UCL Medical School, Windeyer Building, 46 Cleveland Street, London, W1P 6DB UK ‡G.Perkins and L.S.Drury contributed equally to this paper *Corresponding author. E-mail: [email protected] The EMBO Journal (2001)20:4836-4845https://doi.org/10.1093/emboj/20.17.4836 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info The Cdc6 DNA replication initiation factor is targeted for ubiquitin-mediated proteolysis by the E3 ubiquitin ligase SCFCDC4 from the end of G1 phase until mitosis in the budding yeast Saccharomyces cerevisiae. Here we describe a dominant-negative CDC6 mutant that, when overexpressed, arrests the cell cycle by inhibiting cyclin-dependent kinases (CDKs) and, thus, prevents passage through mitosis. This mutant protein inhibits CDKs more efficiently than wild-type Cdc6, in part because it is completely refractory to SCFCDC4-mediated proteolysis late in the cell cycle and consequently accumulates to high levels. The mutation responsible for this phenotype destroys a putative CDK phosphorylation site near the middle of the Cdc6 primary amino acid sequence. We show that this site lies within a novel Cdc4-interacting domain distinct from a Cdc4-interacting site identified previously near the N-terminus of the protein. We show that both sites can target Cdc6 for proteolysis in late G1/early S phase whilst only the newly identified site can target Cdc6 for proteolysis during mitosis. Introduction Precise and tightly controlled DNA replication is an essential feature of the eukaryotic cell cycle. The regulated assembly of pre-replicative complexes (pre-RCs) at origins of DNA replication during the G1 phase is a critical step in this process. In budding yeast the main cyclin (Cln)-dependent kinase (CDK), Cdc28, triggers the initiation of DNA replication from origins containing pre-RCs and, at the same time, prevents the assembly of new pre-RCs (Diffley, 1996, 2001; Dutta and Bell, 1997; Donaldson and Blow, 1999; Pasero and Schwob, 2000). Thus, pre-RCs can assemble only early in G1 phase when Cdc28 kinase activity is low. The Cdc6 protein is required for the assembly of pre-RCs (Cocker et al., 1996; Detweiler and Li, 1997; Tanaka et al., 1997) and Cdc6 levels are tightly regulated during the cell cycle by CDK activity (Piatti et al., 1995; Drury et al., 1997, 2000; Elsasser et al., 1999; Calzada et al., 2000). The CDC6 gene is transcribed periodically in early G1 phase (Zhou and Jong, 1990; Zwerschke et al., 1994; Piatti et al., 1995; McInerny et al., 1997). In addition to this transcriptional regulation, evidence has emerged of an intricate system for ensuring the effective elimination of Cdc6 throughout the cell cycle. We have previously defined three distinct modes of Cdc6 proteolysis based on cis- and trans-acting genetic requirements (Drury et al., 2000). Cdc6 proteolysis during pre-Start G1 (mode 1) is moderately rapid (t1/2 ∼15 min), is independent of the two best-characterized cell cycle-regulated pathways for ubiquitin-mediated proteolysis, the SCF and the APC/cyclosome, and does not require any of the eight consensus Cdc28 phosphorylation sites in Cdc6. Near the end of G1 phase, Cdc6 proteolysis becomes extremely rapid (t1/2 < 2 min). This rapid ‘mode 2’ proteolysis requires SCFCDC4. Mode 2 degradation occurs only after the activation of the G1 cyclin-dependent kinase. Moreover, it requires at least some subset of CDK consensus phosphorylation sites in Cdc6, since a mutant in which all eight consensus sites have been mutated is resistant to mode 2 proteolysis. Whilst it requires G1 cyclins, mode 2 proteolysis does not require the S-phase-specific cyclins Clb5 or Clb6, suggesting that it is direct phosphorylation of Cdc6 by Cln-Cdc28 that targets it for proteolysis. Later in the cell cycle, after activation of the B type cyclins, Cdc6 proteolysis is significantly slower than it is during S phase (t1/2 ∼15 min). This ‘mode 3’ proteolysis, however, is still entirely dependent upon SCFCDC4 and also requires some subset of CDK consensus sites. In our previous work, modes 2 and 3 were distinguished primarily on the basis of proteolysis rate. Here we show that Cdc6 possesses two distinct SCFCDC4-interaction domains, one, previously identified, near the N-terminus of the protein and a second novel domain located near the middle of the protein. Interestingly, this second domain contains two CDK consensus sites and mutation of either site stabilizes the protein during G2/M. Mode 2 proteolysis works through both SCFCDC4 sites but primarily through the first, whereas mode 3 is entirely dependent upon the second. This is a novel mechanism for modulating the rate of SCFCDC4-dependent proteolysis during the cell cycle. Results CDC6-d2 overexpression prevents mitosis To better understand the function and regulation of Cdc6 in DNA replication we isolated and characterized dominant-negative mutant alleles of CDC6 (Perkins and Diffley, 1998). In this screen, a plasmid containing the CDC6 gene under the control of the GAL1,10 promoter was randomly mutagenized by passage through a mutator Escherichia coli strain. This library of mutants was transformed into yeast and plated on glucose-containing plates. Transformants were then replica plated on to galactose-containing plates to allow expression of the mutant proteins. From 20 000 transformants, two candidates were identified that grew on glucose- but not galactose-containing medium. One of these, CDC6-d1, which has previously been described in detail, prevented normal S phase progression by interfering with pre-RC assembly (Perkins and Diffley, 1998). The second, CDC6-d2, is described in this paper. Figure 1A shows that yeast carrying either the wild-type GAL1,10–CDC6 plasmid or the vector alone formed colonies on both glucose- and galactose-containing plates. However, yeast carrying the GAL1,10–CDC6-d2 plasmid grew well on glucose but showed severely retarded growth on galactose-containing plates. Figure 1.(A) W303-1a or W303-1aΔsic1 were transformed with pRS426 (Christianson et al., 1992), pRS426 GAL1,10–CDC6 or pRS426 GAL1,10–CDC6-d2 and grown on glucose (no expression from the GAL1,10 promoter) or galactose to induce expression of the CDC6 gene. Expression of CDC6-d2 but not CDC6 resulted in an inhibition to growth. As can be seen on the right-hand half of each plate this effect was not dependent on SIC1. (B) W303-1a with an integrated copy of either (i) GAL1,10–CDC6 or (ii) GAL1,10–CDC6-d2 was grown in YPRaf until mid-log phase. At this point the cells were transferred into YPGal and allowed to continue cycling. Samples were taken every hour and processed for flow cytometry. Download figure Download PowerPoint To begin to determine the mechanism of growth suppression, we asked whether Cdc6-d2 overexpression arrested cells at a specific stage of the cell cycle. Cells containing either wild-type CDC6 or CDC6-d2 under the control of the GAL1,10 promoter were grown to mid-log phase in raffinose-containing medium and then transferred to fresh medium containing galactose. At the time intervals indicated in Figure 1B, samples were taken and the DNA content was measured by flow cytometry. Figure 1A shows that overexpression of wild-type Cdc6 does not prevent cell proliferation. As shown in Figure 1B, this overexpression does have an effect on cell cycle kinetics as can be seen by the increase in the fraction of cells with a 2C DNA content, consistent with previous work (Bueno and Russell, 1992). The expression of Cdc6-d2, however, prevents proliferation (Figure 1A) and cells accumulate with an apparent 2C DNA content (Figure 1B). In other experiments, when Cdc6-d2 was expressed after release from a nocodazole arrest, cells were unable to complete mitosis, indicating that Cdc6-d2 can block cell cycle progression after S phase is complete (data not shown). Thus, unlike Cdc6-d1, which inhibited S phase but not mitosis, Cdc6-d2 prevents passage through mitosis but does not prevent DNA replication. Microscopic examination revealed that cells expressing GAL1,10–CDC6-d2 developed abnormal cell morphology characterized by the presence of highly elongated buds (Figure 2A). This morphology is similar to that of cdc4 temperature-sensitive mutant cells at the restrictive temperature (Hartwell et al., 1973, 1974; Hereford and Hartwell, 1974; Hartwell, 1976). It is also similar to the phenotype of cells overexpressing the Cdc28-Clb kinase inhibitor (CKI) Sic1 (Schwob et al., 1994; Dahmann et al., 1995; Noton and Diffley, 2000) and of cells bearing mutations that compromise Cdc28-Clb activity (Schwob et al., 1994), presumably because Cdc28-Clb kinase activity inhibits polarized bud growth induced by Cln-Cdc28 kinase (Lew and Reed, 1993, 1995). This phenotype suggested that Cdc6-d2 was causing a G2/M arrest by inhibiting Cdc28-Clb kinase. Cdc6 can interact with and inhibit Cdc28-Clb kinase in vitro (Elsasser et al., 1996; Calzada et al., 2000) and in vivo (Desdouets et al., 1998; Calzada et al., 2000); thus, it was possible that the dominant-negative effect of overexpression of Cdc6-d2 was the result of Cdc28-Clb kinase inhibition. Consistent with this, removal of the N-terminal 47 amino acids of Cdc6-d2, which contain the Cdc28-Clb-interacting domain, eliminates the growth arrest phenotype (data not shown). Figure 2.(A) YGP28 (vector), YGP24 (GAL1,10–CDC6) or YGP25 (GAL1,10–CDC6-d2) cells were grown in YPRaf to mid-log phase and then transferred into either fresh YPRaf or YPGal and allowed to grow for 6 h. Three microlitres from each culture were examined by phase contrast microscopy. (B) YGP28 (lane 3), YGP24 (lane 4) and YGP25 (lane 5) cells were grown in YPRaf to mid-log phase and then blocked in G2/M with nocodozole. Once 90% of the cells had a large budded phenotype they were transferred into YPGal also containing nocodazole. After a further 2.5 h, samples were taken and processed for immunoblotting to examine the phosphorylation status of the DNA polymerase α subunit p86/91. Control samples to visualize the usual pattern of p86/91 phosphorylation in G1 (lane 1) and G2/M (lane 2) cells are also shown. Download figure Download PowerPoint The second largest subunit (B subunit) of DNA polymerase α primase is phosphorylated late in the cell cycle by Cdc28-Clb kinase (Foiani et al., 1995). This phosphorylation causes a shift in mobility in SDS– polyacrylamide gels, and inhibition of Cdc28-Clb kinase in nocodazole-arrested cells is sufficient to cause dephosphorylation of the B subunit (Desdouets et al., 1998). Overexpression of wild-type Cdc6 in nocodazole-arrested cells can drive dephosphorylation of B subunit when SCFCDC4 is inactive (Desdouets et al., 1998). However, Figure 2B, lane 4, shows that overexpression of wild-type Cdc6 in nocodazole-arrested cells does not lead to dephosphorylation of B subunit when SCFCDC4 is active. By contrast, overexpression of the mutant Cdc6-d2 leads to efficient dephosphorylation of B subunit even when SCFCDC4 is active (Figure 2B, lane 5). These results are consistent with the idea that overexpression of Cdc6-d2 blocks cells in G2/M by inactivating Cdc28-Clb kinase. CDK inhibition could be due to direct action of Cdc6 on Cdc28. Alternatively, since both Cdc6 (Piatti et al., 1995; Elsasser et al., 1996; Drury et al., 1997) and the CKI Sic1 (Schwob et al., 1994; Knapp et al., 1996; Verma et al., 1997b) are targeted for degradation by SCFCDC4, the effects might be indirect. That is, overexpression of the mutant Cdc6 might, in some way, interfere with SCFCDC4, causing inappropriate accumulation of Sic1 and consequent cell cycle arrest. Such a mechanism has been shown to explain how overexpression of budding yeast Cdc6 drives re-replication in fission yeast (Wolf et al., 1999a). However, as shown in Figure 1A, overexpression of Cdc6-d2 is still lethal in cells lacking Sic1, thus, the dominant-negative phenotype is not due to stabilization of Sic1. Cdc6-d2 proteolysis does not occur in G2/M but is normal in G1 and S phases The results described above suggest that Cdc6-d2 overexpression prevents entry into mitosis by inactivating Cdc28-Clb kinase. The wild-type Cdc6 protein appears to be less efficient at inhibiting Cdc28-Clb kinase since its overproduction does not block cell proliferation. One possible explanation for this difference might be that the mutant protein is more stable than wild-type Cdc6. This would allow the protein to accumulate to higher levels and, thus, inhibit Cdc28-Clb kinase more effectively. This possibility is consistent with the fact that Cdc6-d2 overexpression in a CDC4+ background results in a phenotype very similar to the overexpression of wild-type Cdc6 in a cdc4 mutant background (Drury et al., 1997; Sanchez et al., 1999). It is also consistent with the fact that Cdc6-d2 accumulates to higher levels than wild-type Cdc6 when expressed in nocodazole-arrested cells (Figure 2B). To test this hypothesis directly, we examined the rate at which wild-type and mutant proteins disappeared in cells arrested in mitosis. In Figure 3A, cells were first arrested with nocodazole in raffinose-containing medium and Cdc6 or Cdc6-d2 was expressed by switching cells to galactose-containing medium for 30 min. Transcription was then repressed by transferring cells to glucose-containing medium and further translation was blocked with cycloheximide. The disappearance of Cdc6 was examined by immunoblot. This experiment shows that, as described previously, the wild-type protein disappears rapidly in nocodazole-arrested cells; however, the mutant Cdc6-d2 protein is almost completely stable in these cells. This experiment indicates that Cdc6-d2 is resistant to mode 3 proteolysis. Figure 3.YGP24 (GAL1,10–CDC6) and YGP25 (GAL1,10–CDC6-d2) cells were grown in YPRaf until mid-log phase, the cultures were then split into two and blocked with either nocodazole (A) or α factor (B). After blocking GAL1,10–CDC6 or GAL1,10–CDC6-d2 was induced by the addition of galactose. Thirty minutes later, transcription from the GAL1,10 promoter and translation were repressed (T = 0). Further samples were taken at the times indicated and processed for immuno blotting. LC is the loading control showing a region of Ponceau-S-stained membrane corresponding to 55–66 kDa. (C) YP25 cells were grown in YPRaf and blocked with α factor to synchronize them. Once the cells were blocked galactose was added to induce expression of GAL1,10–CDC6-d2. After 30 min the cells were washed and released from the block into YPRaf/Gal. Samples were taken at the time of release and every subsequent 10 min to be processed for immuno blotting and to assess the budding index. Download figure Download PowerPoint To determine whether this effect on Cdc6 proteolysis is a specific cell cycle effect or some more general defect, we examined the proteolysis of wild-type and mutant Cdc6 proteins at other points in the cell cycle. In α-factor-arrested cells Cdc6 proteolysis occurs by a pathway (mode 1) that is distinct from mode 3; it is independent of SCFCDC4 and does not require any of the CDK consensus sites in Cdc6. Figure 3B shows that Cdc6 and Cdc6-d2 are both degraded at very similar rates in α-factor-arrested cells. Thus, Cdc6-d2 is not defective as a substrate for mode 1 proteolysis while it is completely defective as a substrate for mode 3 proteolysis. Mode 2 proteolysis during late G1 phase and S phase is more rapid than mode 3 proteolysis but, like mode 3, requires SCFCDC4. We were, therefore, interested in determining whether Cdc6-d2 was generally defective in all SCFCDC4 proteolysis or if it is specifically defective in mode 3 proteolysis. To test this, cells were arrested in G1 with α factor, transferred to galactose-containing medium in α factor and released from the α-factor arrest into fresh galactose-containing medium. In this experiment, therefore, Cdc6 is constitutively expressed during and after release from the G1 arrest. We have shown previously that the very rapid mode 2 proteolysis drastically reduces the steady-state levels of Cdc6 from approximately the time of bud emergence until the end of S phase in such an experiment (Drury et al., 1997, 2000). Figure 3C shows that Cdc6-d2 mutant protein is also unable to accumulate during this time interval. The reduction in Cdc6-d2 levels during S phase is very similar to that seen with the wild-type protein (Drury et al., 2000; and data not shown) indicating that Cdc6-d2 can still be targeted for proteolysis during S phase. At later time points in this experiment, Cdc6-d2 accumulates to quite high levels, consistent with a defect in degradation later in the cell cycle. Thus, Cdc6-d2 is specifically defective as a substrate for mode 3 proteolysis and is not affected for mode 1 or 2 proteolysis. The mutation in Cdc6-d2 identifies a CDK consensus site required for mode 3 proteolysis DNA sequence analysis of the CDC6-d2 allele identified a single point mutation causing a change from C to T at bp 1103, which resulted in a replacement of threonine at amino acid 368 with methionine (Figure 4A). Cdc6 contains eight SP or TP motifs that could potentially serve as CDK phosphorylation sites; the mutation in Cdc6-d2 destroys the seventh of these sites. This site is not a ‘complete’ consensus site since it does not contain a basic residue at the +3 position (Langan et al., 1989; Shenoy et al., 1989). Cdc6 is a member of a superfamily of ATPases (the AAA+ family) characterized by an extensive region of homology (Perkins and Diffley, 1998; Neuwald et al., 1999). The mutation in Cdc6-d2 occurs ∼30 amino acids C-terminal to this region of similarity. In a 50 amino acid residue region surrounding this mutation, there are six proline and three glycine residues, suggesting that this region may be unstructured. There are two other SP motifs in this region and we were interested in determining whether mutation of these sites also affected the stability of Cdc6. To examine this we used site-directed mutagenesis to construct two alleles of CDC6, changing serine 354 to alanine in one case (S354A) and serine 372 to alanine in the other (S372A). Figure 4C shows that Cdc6-S354A was highly unstable in nocodazole-arrested cells, similar to wild-type Cdc6. However, Cdc6-S372A was significantly more stable under these conditions, though less stable than Cdc6-d2 (compare Figure 3A with 4B). Thus CDK sites seven and eight both contribute to proteolysis during mitosis. Figure 4.(A) A schematic diagram to show the relative positions of the eight S/TP motifs in Cdc6. The amino acid sequence around sites 7 and 8 is shown and the arrow denotes a T to M substitution at amino acid position 368 caused by the mutation in CDC6-d2. Amino acid residue numbers are at the top of the diagram; the region of similarity in various AAA+ family members is indicated as a grey box (Perkins and Diffley, 1998; Neuwald et al., 1999). (B) GAL1,10 promoter shut-off experiments with cells blocked in G2/M by nocodazole and expressing either GAL1,10–CDC6-S354A (phosphorylation site 6) or GAL1,10–CDC6-S372A (phosphorylation site 8). Transcription and translation were repressed and a sample was taken (T = 0) to be processed for immunoblotting. Subsequent samples were taken at the times indicated. Download figure Download PowerPoint Cdc6 contains two separate Cdc4p-interaction domains Our previous analysis had suggested that the N-terminal 47 amino acids of Cdc6 played an important role in SCFCDC4-dependent proteolysis, thus it was somewhat surprising to find that sequences in the middle of the protein were also involved in proteolysis. We showed previously that the N-terminal 47 amino acids of Cdc6 interacted with Cdc4 in a two-hybrid assay and that the strongest interaction required sequences between amino acids 17 and 47 (Drury et al., 1997). We noticed a short region of sequence similarity between this region and the region encompassing the mutation in Cdc6-d2 (Figure 5A). This sequence contains an incomplete CDK consensus site (without the basic residue at +3) followed by a complete consensus site. We were interested in whether this sequence comprises a hitherto unidentified Cdc4-interaction domain. To address this, we fused a 50 amino acid polypeptide encompassing this sequence to the LexA DNA binding domain and examined its ability to interact with Cdc4 in a two-hybrid experiment. Figure 5B shows that, like the N-terminal 47 amino acids of Cdc6, amino acids 341–390 interacted strongly with Cdc4, indicating that this region can act as a Cdc4-interaction domain in vivo. Figure 5.(A) Similarity of a Cdc4-interaction domain in the N-terminus of Cdc6 with sequence around the mutation in Cdc6-d2. The numbers denote the amino acid in Cdc6 at the start and finish of the two sequences. (B) Two-hybrid analysis with these two regions of Cdc6. Download figure Download PowerPoint Interaction of SCFCDC4 with substrates such as Sic1 requires phosphorylation at CDK sites (Feldman et al., 1997; Skowyra et al., 1997; Verma et al., 1997a). We considered the possibility that mutation of CDK sites 7 and 8, which causes stabilization of Cdc6 in nocodazole-arrested cells, might affect interaction with Cdc4. To examine this, polypeptides corresponding to amino acid residues 341–390 but containing single amino acid substitutions in the CDK consensus sites were tested for their ability to interact with Cdc4 in the two-hybrid system. Figure 5B shows that mutation of either phosphorylation site dramatically reduced Cdc4 interaction. The T368M mutant (from Cdc6-d2), which in the context of the full-length protein is completely stable in nocodazole-arrested cells (Figure 3A), shows no detectable interaction with Cdc4, while the S372A mutant, which is more stable but not completely stable (Figure 4B), still shows weak interaction. Thus, there is a strong correlation between stability in G2/M and ability to interact with Cdc4. The results described above strongly suggest that Cdc6 contains an additional Cdc4-interaction domain between amino acids 341 and 390, which is critical for mode 3 proteolysis. The existence of a functionally important Cdc4-interaction domain in addition to the N-terminal site is supported by several other experiments. First, Figure 6A shows that a polypeptide containing the N-terminal 47 amino acids of Cdc6 interacts with Cdc4 in the two-hybrid system and, consistent with the importance of CDK phosphorylation, mutation of the four SP/TP motifs in this polypeptide abrogates this interaction. However, as shown in Figure 6B, when these four mutations are engineered into the full-length Cdc6 protein, the resulting protein is as rapidly degraded in nocodazole-arrested cells as it is in α-factor-arrested cells. As shown in Figure 6C, degradation of this protein in nocodazole-arrested cells is still completely dependent upon Cdc4, arguing strongly that there must be an additional Cdc4-interaction site in the protein. Secondly, we had previously shown that deletion of the N-terminal 47 amino acids of Cdc6 significantly stabilized the protein in nocodazole-arrested cells. We noted, however, that this truncated protein was still degraded, although the degradation was significantly slower (Drury et al., 1997). Furthermore, the degradation of this truncated protein was faster in nocodazole-arrested cells than it was in α-factor-arrested cells. In these original experiments, we were not adding cycloheximide at the time of transcriptional repression to prevent further translation of stable messages. Using cycloheximide, in Figure 6D we show that this truncated protein is, indeed, degraded in nocodazole-arrested cells although the rate of degradation is considerably slower than the rate for full-length protein (compare Figures 3A and 6D). Moreover, mutation of the remaining four CDK consensus sites in this truncated protein renders it completely stable in nocodazole-arrested cells. Although we do not know why the truncated protein is degraded more slowly than the full-length protein, we note that this truncation also removes a putative nuclear localization signal that resides in the N-terminal 47 amino acids (Jong et al., 1996). Regardless, these experiments, taken together, demonstrate the existence of a second, functionally important Cdc4-interaction domain between amino acids 341 and 390, which contains two critical CDK phosphorylation sites. Figure 6.(A) The requirement for the S/TP motifs in the N-terminal fragment of Cdc6 was tested in a two-hybrid assay with Cdc4p. The top row shows the two-hybrid interaction between the N-terminus of Cdc6 and Cdc4p described previously. In the second row the N-terminus but with the S/TP motifs mutated to A[S/TP(1–4)A] does not interact with GAD-Cdc4. (B) Promoter shut-off experiments with Cdc6-S/TP(1–4)A in cells blocked in G1 or G2/M show that these motifs are not required for instability in G1 or G2/M. However, this instability is dependent on CDC4 (C) in G2/M since Cdc6-S/TP(1–4)A is stable in cdc4ts cells blocked in nocodazole. (D) Cdc6ΔNT is more stable than the full-length protein. It is, however, degraded at a slower rate as can be seen above in a promoter shut-off in G2/M blocked cells. Mutation of the remaining S/TP(5–8)A in this truncated protein stabilizes it. Download figure Download PowerPoint Our results thus far show that Cdc6 contains two Cdc4-interaction domains; one is located in the N-terminal 47 amino acids (Cdc4 site 1) and one is located between amino acids 341 and 390 (Cdc4 site 2). We have shown that mutation which abrogates Cdc4 site 2 interaction (i.e. Cdc6-d2) prevents SCFCDC4-dependent mode 3 degradation in nocodazole-arrested cells but not SCFCDC4-dependent mode 2 degradation during S phase. Conversely, mutations that abrogate Cdc4 site 1 interaction [i.e. Cdc6S/TP(1–4)A] do not affect SCFCDC4-dependent mode 3 degradation in nocodazole-arrested cells. Thus, we were interested in determining whether the degradation of this mutant during S phase by mode 2 was affected. Figure 7A shows that the levels of this mutant protein, when constitutively expressed, are significantly reduced during S phase although these levels are not reduced to the same extent as the wild-type protein, suggesting some role for site 1 in mode 2 proteolysis. However, this experiment, together with the experiment in Figure 3C, shows that neither of the two Cdc4-interaction sites is sufficient to account fully for mode 2. Thus, we considered the possibility that either site can target Cdc6 for mode 2 proteolysis. To test this, we examined the proteolysis of a Cdc6 mutant in which both Cdc4-interaction sites are inactivated by mutation of the important CDK consensus sites. To do this, all four CDK sites in the N-terminus, together with CDK site 7, were mutated. Figure 7B shows that, unlike mutants in either site 1 or site 2 alone, this protein is stable during S phase. Thus, these two Cdc4-interaction sites act redundantly during S phase. Figure 7.(A) YLD66 cells grown in YPRaf were synchronized with α factor. Once the cells were blocked, galactose was added to induce the Cdc6-S/TP(1–4)A protein. After a further 30 min the cells were released from the block into YPRaf/Gal. Samples were taken at the time of release (T = 0) and every 10 min after for a duration of 90 min to assess the budding index and for immunoblotting to detect levels of Cdc6-S/TP(1–4)A. (B) A similar experiment was performed with strain YLD69 [GAL1,10–CDC6-S/TP(1–4)A,d2]. Download figure Download PowerPoint Discussion The proteolysis of the budding yeast Cdc6 protein is under surprisingly complex regulation. Previously, we distinguished two distinct modes of SCFCDC4-dependent Cdc6 proteolysis during late G1/early S phase and during G2/M primarily on the basis of degradation rate. Here, we have extended this distinction by showing that Cdc6 is targeted for SCFCDC4-dependent degradation by two different SCFCDC4-interaction domains, which are regulated differently during the cell cycle. One of these interaction domains, in the N-terminal 47 amino acids, is only utilized during late G1 and S phases while the other, located in the middle of the primary amino acid sequence is utilized from late G1 through mitosis (see Figure 7A). As a consequence, Cdc6 proteolysis during late G1/S phase is not dependent upon eithe" @default.
• W1967579846 created "2016-06-24" @default.
• W1967579846 creator A5045464073 @default.
• W1967579846 date "2001-09-03" @default.
• W1967579846 modified "2023-10-18" @default.
• W1967579846 title "Separate SCFCDC4 recognition elements target Cdc6 for proteolysis in S phase and mitosis" @default.
• W1967579846 cites W1520741384 @default.
• W1967579846 cites W1547033864 @default.
• W1967579846 cites W1572585912 @default.
• W1967579846 cites W1579608990 @default.
• W1967579846 cites W1875835053 @default.
• W1967579846 cites W1928704095 @default.
• W1967579846 cites W1932599569 @default.
• W1967579846 cites W1962559236 @default.
• W1967579846 cites W1964429281 @default.
• W1967579846 cites W1966034049 @default.
• W1967579846 cites W1981802723 @default.
• W1967579846 cites W1983222046 @default.
• W1967579846 cites W1993464551 @default.
• W1967579846 cites W1993882349 @default.
• W1967579846 cites W1997973407 @default.
• W1967579846 cites W1999360313 @default.
• W1967579846 cites W2002315746 @default.
• W1967579846 cites W2014463884 @default.
• W1967579846 cites W2014705255 @default.
• W1967579846 cites W2017816163 @default.
• W1967579846 cites W2020613572 @default.
• W1967579846 cites W2023296349 @default.
• W1967579846 cites W2025011614 @default.
• W1967579846 cites W2026160273 @default.
• W1967579846 cites W2027399788 @default.
• W1967579846 cites W2033228162 @default.
• W1967579846 cites W2039958767 @default.
• W1967579846 cites W2056205588 @default.
• W1967579846 cites W2057594508 @default.
• W1967579846 cites W2062319807 @default.
• W1967579846 cites W2074126694 @default.
• W1967579846 cites W2075408326 @default.
• W1967579846 cites W2080835326 @default.
• W1967579846 cites W2087656195 @default.
• W1967579846 cites W2091512138 @default.
• W1967579846 cites W2092611033 @default.
• W1967579846 cites W2095934571 @default.
• W1967579846 cites W2097164868 @default.
• W1967579846 cites W2099357760 @default.
• W1967579846 cites W2105022572 @default.
• W1967579846 cites W2107325325 @default.
• W1967579846 cites W2114685781 @default.
• W1967579846 cites W2116808406 @default.
• W1967579846 cites W2122073313 @default.
• W1967579846 cites W2125145813 @default.
• W1967579846 cites W2128276755 @default.
• W1967579846 cites W2135166443 @default.
• W1967579846 cites W2143955948 @default.
• W1967579846 cites W2151479322 @default.
• W1967579846 cites W2159137674 @default.
• W1967579846 cites W2165155144 @default.
• W1967579846 cites W2168545181 @default.
• W1967579846 cites W2170085122 @default.
• W1967579846 cites W2171202879 @default.
• W1967579846 cites W2434643092 @default.
• W1967579846 cites W29290466 @default.
• W1967579846 cites W4231463317 @default.
• W1967579846 cites W71175735 @default.
• W1967579846 doi "https://doi.org/10.1093/emboj/20.17.4836" @default.
• W1967579846 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/125267" @default.
• W1967579846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11532947" @default.
• W1967579846 hasPublicationYear "2001" @default.
• W1967579846 type Work @default.
• W1967579846 sameAs 1967579846 @default.
• W1967579846 citedByCount "101" @default.
• W1967579846 countsByYear W19675798462012 @default.
• W1967579846 countsByYear W19675798462013 @default.
• W1967579846 countsByYear W19675798462014 @default.
• W1967579846 countsByYear W19675798462015 @default.
• W1967579846 countsByYear W19675798462016 @default.
• W1967579846 countsByYear W19675798462017 @default.
• W1967579846 countsByYear W19675798462018 @default.
• W1967579846 countsByYear W19675798462019 @default.
• W1967579846 countsByYear W19675798462020 @default.
• W1967579846 countsByYear W19675798462021 @default.
• W1967579846 countsByYear W19675798462022 @default.
• W1967579846 crossrefType "journal-article" @default.
• W1967579846 hasAuthorship W1967579846A5045464073 @default.
• W1967579846 hasBestOaLocation W19675798462 @default.
• W1967579846 hasConcept C181199279 @default.
• W1967579846 hasConcept C2781307694 @default.
• W1967579846 hasConcept C54355233 @default.
• W1967579846 hasConcept C55493867 @default.
• W1967579846 hasConcept C70721500 @default.
• W1967579846 hasConcept C86803240 @default.
• W1967579846 hasConcept C93304396 @default.
• W1967579846 hasConcept C95444343 @default.
• W1967579846 hasConceptScore W1967579846C181199279 @default.
• W1967579846 hasConceptScore W1967579846C2781307694 @default.
• W1967579846 hasConceptScore W1967579846C54355233 @default.
• W1967579846 hasConceptScore W1967579846C55493867 @default.
• W1967579846 hasConceptScore W1967579846C70721500 @default.

• next